Drug Trial Radar · NCT05222932
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Mar 8, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- TILT Biotherapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.
Conditions
- Melanoma
- Head and Neck Squamous Cell Carcinoma
Interventions
TILT-123Biological
TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
AvelumabDrug
Anti-PDL1 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with any (serious and non-serious) Adverse Events.Time frame: 85 days
- Number of Participants with abnormal laboratory values.Time frame: 85 days
- Number of Participants with vital sign abnormalities.Time frame: 85 days
- Number of Participants with Adverse Events assessed by 12- lead electrocardiograms (ECGs)Time frame: 85 days
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Memorial Sloan Kettering Cancer Center
New York, New York
Docrates Cancer Center
Helsinki, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.